Evidence map›Paper›PMID 34707909›Full record

ArticleSchizophrenia research and treatment2021

Homocysteine in Schizophrenia: Independent Pathogenetic Factor with Prooxidant Activity or Integral Marker of Other Biochemical Disturbances?

T V Zhilyaeva, A S Piatoikina, A P Bavrina, O V Kostina, E S Zhukova, T G Shcherbatyuk, A S Blagonravova, E E Dubinina, G E Mazo

Open access · hybridAbstract read
In one paragraph

Article in Schizophrenia research and treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Controlling the Impact ofMedicina (Kaunas, Lithuania) · 2023
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

T V ZhilyaevaPrivolzhsky Research Medical University, Russia.ORCID https://orcid.org/0000-0001-6155-1007
A S PiatoikinaNizhny Novgorod Clinical Psychiatric Hospital No. 1, Russia.ORCID https://orcid.org/0000-0002-8932-7418
A P BavrinaPrivolzhsky Research Medical University, Russia.ORCID https://orcid.org/0000-0002-8775-7297
O V KostinaPrivolzhsky Research Medical University, Russia.ORCID https://orcid.org/0000-0001-7529-2544
E S ZhukovaNizhny Novgorod Research Institute for Hygiene and Occupational Pathology, Russia.ORCID https://orcid.org/0000-0002-9016-2390
T G ShcherbatyukNizhny Novgorod Research Institute for Hygiene and Occupational Pathology, Russia.ORCID https://orcid.org/0000-0003-1144-8006
A S BlagonravovaPrivolzhsky Research Medical University, Russia.ORCID https://orcid.org/0000-0002-1467-049X
E E DubininaV.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Russia.ORCID https://orcid.org/0000-0001-8906-5596
G E MazoV.M. Bekhterev National Medical Research Center for Psychiatry and Neurology, Russia.ORCID https://orcid.org/0000-0001-7910-9129
Privolzhsky Research Medical University · RUSt.Petersburg V.M.Bekhterev Psychoneurological Research Institute · RUMoscow Region State University · RUNizhny Novgorod Research Institute of Traumatology and Orthopedics · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A wide range of studies have demonstrated that hyperhomocysteinemia is associated with the risk of schizophrenia, but currently available assumptions about the direct involvement of homocysteine (Hcy) in the pathogenesis of schizophrenia are hypothetical. It is possible that in vivo Hcy is only a marker of folate metabolism disturbances (which are involved in methylation processes) and is not a pathogenetic factor per se. Only one study has been conducted in which associations of hyperhomocysteinemia with oxidative stress in schizophrenia (oxidative damage to protein and lipids) have been found, and it has been suggested that the oxidative stress may be induced by the elevated Hcy in schizophrenic patients. But the authors did not study the level of reduced glutathione (GSH), as well as possible causes of hyperhomocysteinemia-disturbances of folate metabolism. The aim of this work is to analyze the association of Hcy levels with the following: (1) redox markers in schizophrenia GSH, markers of oxidative damage of proteins and lipids, and the activity of antioxidant enzymes in blood serum; (2) with the level of folate and cobalamin (В12); and (3) with clinical features of schizophrenia measured using the Positive and Negative Syndrome Scale (PANSS). 50 patients with schizophrenia and 36 healthy volunteers, matched by sex and age, were examined. Hcy in patients is higher than in healthy subjects (

Identifiers

PMID34707909
PMCPMC8545596
OpenAlexW3207836557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.